Novo Nordisk Pushes Deeper Into Obesity Science as Washington’s Pricing Hammer Looms

The Danish drugmaker is broadening its assault on weight management with a novel Phase 3 trial, even as a widening US drug-discount programme threatens to clamp down on the revenue that pays for the research. On 18 May 2026, Novo Nordisk began recruiting patients for the AMAZE-12 study, which tests Amycretin – a dual GLP-1/amylin receptor agonist – not for initial weight loss, but for keeping kilograms off after a diet. It is a commercially untapped niche and a deliberate bet on durability.

Early evidence supports the logic. In a Phase 1b/2a trial, weekly injections of Amycretin produced a 22% weight reduction after 36 weeks. An oral version delivered 13.1% after 12 weeks of daily dosing. The molecule, internally designated NNC0487-0111, aims to combine two appetite-control signals in one shot, potentially simplifying manufacturing and opening the door to a pill. Success would make Amycretin the third pillar alongside Wegovy and the CagriSema combination.

That combination therapy, CagriSema – pairing Cagrilintide with semaglutide – is meanwhile on a tight regulatory clock. The FDA is expected to rule on its approval this year, while a higher-dose Phase 3 study is scheduled for the second half of 2026. Larger REDEFINE-11 data are due in the first half of 2027. Novo is also running a mechanistic study of Cagrilintide alone to better understand how it suppresses hunger and food intake.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Politically, however, the winds have shifted. Reports of a massive expansion to the US government’s drug price discount programme have weighed on the entire pharmaceutical sector. Novo already offers rebates in exchange for tariff exemptions; a broader scheme would squeeze its already soft 2026 revenue outlook. The stock has fallen roughly 14% since the start of the year, trading at €38.45 and sitting below its 200-day moving average.

Management is trying to shore up confidence through buybacks. In mid-May it bought back about 1.24 million shares as part of a 15 billion Danish kroner repurchase programme. But the combination of pipeline promise and near-term pricing risk has left the stock searching for a floor.

Investors will get a clearer picture when the company publishes first-half results on 5 August 2026. Those numbers will reveal how much the US discount programme has already carved into margins. Meanwhile, the regulatory calendar stays crowded: Novo secured six approvals and launched more than ten clinical trials in the first quarter alone. The first major readout for Amycretin is not expected until 2027, meaning the market must balance hope against real-world headwinds for months to come.

Ad

Novo Nordisk Stock: New Analysis - 20 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69384075 |